Serial No.: 09/336,091 ' -2 - Art Unit: 1644

Conf. No.: 7247

## In the Claims

Please replace all prior versions, and listings, of claims in the application with the following list of claims:

- 1. (Canceled)
- 2. (Currently amended) An isolated HLA DRB1\*15-binding peptide consisting of the amino acid sequence set forth as SEQ ID NO:7, or a functional variant thereof consisting of one amino acid addition or substitution, and

0-10 amino acids added to either or both ends of the amino acid sequence set forth as SEQ ID NO:7, or the functional variant thereof consisting of one amino acid addition or substitution.

- 3-6. (Canceled)
- 7. (Previously presented) The isolated HLA DRB1\*15-binding peptide of claim 2 wherein the isolated peptide is non-hydrolyzable.
- 8. (Canceled)
- 9. (Currently amended) A composition comprising an isolated MAGE-A1 HLA class I-binding peptide and an isolated MAGE-A1 HLA DRB1\*15-binding peptide, wherein the isolated HLA class II-binding peptide consists of

the amino acid sequence set forth as SEQ ID NO:7, or a functional variant thereof consisting of one amino acid addition or substitution, and

0-10 amino acids added to either or both ends of the amino acid sequence set forth as SEQ ID NO:7, or the functional variant thereof consisting of one amino acid addition or substitution, and

wherein the HLA class I-binding peptide and the HLA class II MAGE-A1 HLA DRB1\*15-binding peptide are separate isolated peptides.

10-76. (Canceled)

Serial No.: 09/336,091 - 3 - Art Unit: 1644

Conf. No.: 7247

77. (Previously presented) The isolated HLA DRB1\*15-binding peptide of claim 2 wherein the isolated peptide consists of an amino acid sequence selected from the group consisting of SEQ ID NO:3, SEQ ID NO:4 and SEQ ID NO:7.

## 78. (Canceled)

79. (Previously presented) The isolated HLA DRB1\*15-binding peptide of claim 7 wherein the isolated peptide is selected from the group consisting of peptides comprising D-amino acids, peptides comprising a -psi[CH<sub>2</sub>NH]-reduced amide peptide bond, peptides comprising a -psi[COCH<sub>2</sub>]-ketomethylene peptide bond, peptides comprising a -psi[CH(CN)NH]-(cyanomethylene)amino peptide bond, peptides comprising a -psi[CH<sub>2</sub>CH(OH)]-hydroxyethylene peptide bond, peptides comprising a -psi[CH<sub>2</sub>O]-peptide bond, and peptides comprising a -psi[CH<sub>2</sub>S]-thiomethylene peptide bond.

## 80.-81 (Canceled)

82. (Previously presented) The composition of claim 9 wherein the isolated MAGE-A1 HLA DRB1\*15-binding peptide consists of an amino acid sequence selected from the group consisting of SEQ ID NO:3, SEQ ID NO:4 and SEQ ID NO:7.

## 83.-87. (Canceled)

88. (New) An isolated HLA DRB1\*15-binding peptide consisting of the amino acid sequence set forth as SEQ ID NO:7 with 0-10 amino acids added to either or both ends of the amino acid sequence set forth as SEQ ID NO:7, and

an endosomal targeting signal comprising an endosomal targeting portion of human invariant chain Ii or LAMP-1.

- 89. (New) The isolated HLA DRB1\*15-binding peptide of claim 88 wherein the amino acid sequence is selected from the group consisting of SEQ ID NO:3, SEQ ID NO:4, and SEQ ID NO:7.
- 90. (New) The isolated HLA DRB1\*15-binding peptide of claim 88 wherein the isolated peptide is non-hydrolyzable.

Serial No.: 09/33.6,091 - 4 - Art Unit: 1644

Conf. No.: 7247

91. (New) The isolated HLA DRB1\*15-binding peptide of claim 90 wherein the isolated peptide is selected from the group consisting of peptides comprising D-amino acids, peptides comprising a -psi[CH<sub>2</sub>NH]-reduced amide peptide bond, peptides comprising a -psi[COCH<sub>2</sub>]-ketomethylene peptide bond, peptides comprising a -psi[CH(CN)NH]-(cyanomethylene)amino peptide bond, peptides comprising a -psi[CH<sub>2</sub>CH(OH)]-hydroxyethylene peptide bond, peptides comprising a -psi[CH<sub>2</sub>C]-peptide bond, and peptides comprising a -psi[CH<sub>2</sub>S]-thiomethylene peptide bond.

- 92. (New) A composition comprising
  an isolated MAGE-A1 HLA class I-binding peptide, and
  the isolated MAGE-A1 HLA DRB1\*15-binding peptide of claim 88,
  wherein the HLA class I-binding peptide and the MAGE-A1 HLA DRB1\*15-binding
  peptide are separate isolated peptides.
- 93. (New) The composition of claim 92 wherein the amino acid sequence selected from the group consisting of SEQ ID NO:3, SEQ ID NO:4, and SEQ ID NO:7.
- 94. (New) The composition of claim 92 wherein the isolated peptide is non-hydrolyzable.
- 95. (New) The composition of claim 94 wherein the isolated peptide is selected from the group consisting of peptides comprising D-amino acids, peptides comprising a -psi[CH<sub>2</sub>NH]-reduced amide peptide bond, peptides comprising a -psi[COCH<sub>2</sub>]-ketomethylene peptide bond, peptides comprising a -psi[CH(CN)NH]-(cyanomethylene)amino peptide bond, peptides comprising a -psi[CH<sub>2</sub>CH(OH)]-hydroxyethylene peptide bond, peptides comprising a -psi[CH<sub>2</sub>O]-peptide bond, and peptides comprising a -psi[CH<sub>2</sub>S]-thiomethylene peptide bond.